1[1]Harris N,Jaffe E,Stein H,et al.A revised European-Amreican classification of lymphoid neoplasms:A proposal from the International Lymphoma Study Group.Blood,1994,84:1361
2[2]Jaffe E,Harris N,Diebold J,et al.World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:A progress report.Am J Clin Pathol,1999,111(Suppl 1):S8
3[3]Ghielmini M,Schmitz S,Cogliatti S,et al.Prolonged treatment with 2-monthly rituximab significantly improves eventfree survival and duration of response in patients with follicular lymphoma:A randomized SAKK Trial.Blood,2002 (Abstr),100:161A
4[4]Witzig T,Vukov A,Habermann T,et al.Rituximab therapy for patients with newly diagnosed,asymptomatic advancedstage follicular gradel non-Hodgkin's lymphoma (NHL):A phase Ⅱ trial in the the North Central Cancer Treatment Group(NCCTG).Blood,2002 (Abstr),100:361A
5[5]Solal-Celigny P,Salles GA,Brousse N et al.Single 4-dose rituximab treatment for low tumor burden lymphoma (FL):Survival analyses with a follow-up (F/Up) of at least 5 years.Blood,2004,104 (Abstr):585
6[6]Hiddemann W,Forstpointner R,Kneba M,et al.The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma:Results of two prospective randomized studies of the German Low Grade Lymphoma Study (GLSG).Blood,2004,Abstract # 161
7[7]McLaughlin P,Grillo-López A,Link B,et al.Rituximab Chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:Half of patients respond to a four-dose treatment program.J Clin Oncol,1998,16:2825
8[8]Marcus R,Hagenbeek A,Eghbali H,et al.Fludarabine versus CVP in newly diagnosed patients with stages Ⅲ/Ⅳ nonHodgkin's Lymphoma:Final analysis of prospective randomized phase Ⅲ intergroup study.Ann Oncol,2002,13 (Suppl.2):181 (Abstr)
9[9]Zinzani PL,Pulsoni A,Perrotti A,et al.Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.J Clin Oncol,2004,22:2662
10[10]Czuczman M,Fallon A,Mohr A,et al.Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.Semin Oncol,2002,29 (Suppl 2):36
3Hiddeman W,Unterhah M,Pott C,et al .Fludarabine single-agent phase Ⅱ study of the German low-grade non-Hodgkin's lymphoma study group[J].Sem in Oncol,1993,20(53):28-31.
4Velasguez WS, Lew D, Grogan TM, et al. Combination of fludarabine and mitoxantrone in untreated stages Ⅲ and Ⅳ low-grade lymphoma:s9501 [J].J Clin Oncol,2003,21 (10): 1996-2003.
5Mclaughlin P, Hagemeister FB,Romaguera JE,et al. Fludarabine mitoxantrone and dexamethasone an effective new regimen for indolent lymphoma [J]. J Clin Oncol, 1996, 14(4): 1262-1268.
6Zinzani PL, Bendandi M,Magagnoli M, et al. Fludarabine-mitoxantrone combinatination-containing regimen in recurrent low-grade non-hodgkin's lymphoma [J]. Ann Oncol 1997, 8 (4):379-383.
7Ma SY,AU WY,Chim CS, et al. Fludarabine mitoxantrone and dexamethasone in the treatment of indolent B- and T- cell lymphoid malignancies in Chinese patients [J]. Br J Haematal, 2004,124(6):754-761.
8Hochster HS, Oken mM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in previously untreated low-grade lymphoma: results and long-term follow-up-a repart from the eaotern cooperative Oncology Group[J].J Clin Oncol,2000,18:987-994.
9Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's staging classification [J].Cancer Res, 1971,31(11): 1860-1861.
10Shaikh AJ, Masood N, Ahsan A, et al. Primary cutaneous B cell lymphoma--leg type (NEW EORTC--WHO classifi- cation), with nasal sinuses involvement[J]. J Pak Med Assoc, 2008,58(5):274-276.
